Sign in

    Matthew Keller • H.C. Wainwright & Co., LLC

    Matthew Keller is an analyst at H.C. Wainwright & Co., specializing in equity research within the general sector and notably covering companies such as FibroGen (FGEN) among others in the healthcare space. Keller has made several equity recommendations with a track record showing an overall average return of 9.69% and a Smart Score of 56.3%, while TipRanks data notes a success rate of 0% and an average return per transaction of -34.5% across four ratings. He began his tenure at H.C. Wainwright in the early 2020s, and while specific prior experience is not listed in available sources, his professional credentials likely include standard FINRA securities licenses typical for U.S.-based equity analysts. Despite not having notable industry awards or public recognitions, he continues to provide published coverage and ratings for public companies tied to his sector specialization.

    Matthew Keller's questions to Acurx Pharmaceuticals Inc (ACXP) leadership

    Matthew Keller's questions to Acurx Pharmaceuticals Inc (ACXP) leadership • Q2 2025

    Question

    Matthew Keller from H.C. Wainwright & Co., LLC asked for any additional feedback from the physician community on the recent Lancet publication and inquired about any remaining rate-limiting steps before initiating the Phase 3 studies for ibezapolstat.

    Answer

    Co-Founder, President, CEO & Director David Luci addressed the rate-limiting steps, explaining that the only remaining task is the 'fill finish' of the ibezapolstat drug supply. He noted this step has been intentionally postponed to maximize the drug's shelf life for the trials and is not a significant hurdle, estimating it would be a couple-month process. Mr. Luci also confirmed that both the FDA and European Medicines Agency have agreed on an identical protocol for the Phase 3 trials.

    Ask Fintool Equity Research AI

    Matthew Keller's questions to FibroGen Inc (FGEN) leadership

    Matthew Keller's questions to FibroGen Inc (FGEN) leadership • Q2 2025

    Question

    Matthew Keller from H.C. Wainwright & Co., LLC asked for an update on the feedback received from the physician community regarding the FG3246 Phase 1 data since its publication in the Journal of Clinical Oncology.

    Answer

    CEO Thane Wettig responded that feedback from key advisors and clinical trial sites has been encouraging. He highlighted the dose-response signal observed in the Phase 1 data and noted that physicians are particularly excited about FG3246 as a non-PSMA targeted therapy for metastatic castration-resistant prostate cancer. Executive Director Carol Gaddum added that site feedback during Phase 2 preparation has been very positive, confirming the significant unmet need in the space.

    Ask Fintool Equity Research AI

    Matthew Keller's questions to FibroGen Inc (FGEN) leadership • Q1 2025

    Question

    Matthew Keller inquired about any remaining rate-limiting steps before initiating the FG-3246 Phase 2 monotherapy study and asked for an updated view on the evolving commercial opportunity for the companion diagnostic, FG-3180.

    Answer

    CEO Thane Wettig identified the closing of the FibroGen China transaction as the primary factor gating the rapid start of the Phase 2 trial, noting the recent IND clearance for FG-3180 was a positive step. Regarding FG-3180's commercial potential, Wettig highlighted that the upcoming trial will be crucial for correlating CD46 expression with ADC response. He pointed to the >$1.5 billion PSMA PET agent market as a potential analogue, pending performance data. CFO David DeLucia added that more patient data will clarify its use in future studies.

    Ask Fintool Equity Research AI

    Matthew Keller's questions to Iterum Therapeutics PLC (ITRM) leadership

    Matthew Keller's questions to Iterum Therapeutics PLC (ITRM) leadership • Q1 2025

    Question

    Matthew Keller of H.C. Wainwright & Co. asked for an update on the maturity of discussions with potential commercial partners and inquired about any significant rate-limiting steps ahead of the planned ORLYNVAH launch.

    Answer

    CEO Corey Fishman stated that while business development remains an ongoing opportunity, no acceptable partnership deal has been reached, prompting the company to prepare for a direct launch. He assured that there are no major hurdles or impediments to launching ORLYNVAH by the fourth quarter of 2025, highlighting that the product is already manufactured and available.

    Ask Fintool Equity Research AI